Table 2.
On-demand treatments used for unique attacks, overall and by country
| n (%) | Overall (N = 545) | US (n = 140) | Canada (n = 112) | Germany (n = 74) | Australia (n = 103) | UK (n = 116) |
|---|---|---|---|---|---|---|
| Yes | 421 (77.2) | 112 (80.0) | 58 (51.8) | 45 (60.8) | 90 (87.4) | 116 (100) |
| C1-INH: Berinert® | 257 (61.0) | 20 (17.9) | 55 (94.8) | 42 (93.3) | 52 (57.8) | 88 (75.9) |
| Intravenous | 249 (96.9) | 20 (100) | 47 (85.5) | 42 (100) | 52 (100) | 88 (100) |
| Subcutaneousa | 8 (3.1) | 0 | 8 (14.5) | 0 | 0 | 0 |
| Icatibant | 99 (23.5) | 60 (53.6) | 1 (1.7) | 3 (6.7) | 33 (36.7) | 2 (1.7) |
| C1-INH: Cinryze® | 51 (12.1) | 24 (21.4) | 0 | 0 | 1 (1.1) | 26 (22.4) |
| Androgens | 7 (1.7) | 2 (1.8) | 2 (3.4) | 0 | 3 (3.3) | 0 |
| Ecallantide | 4 (1.0) | 4 (3.6) | 0 | 0 | 0 | 0 |
| Fresh frozen plasma | 3 (0.7) | 2 (1.8) | 0 | 0 | 1 (1.1) | 0 |
| No | 54 (9.9) | 11 (7.9) | 6 (5.4) | 27 (36.5) | 10 (9.7) | 0 |
| Unknown | 70 (12.8) | 17 (12.1) | 48 (42.9) | 2 (2.7) | 3 (2.9) | 0 |
C1-INH C1 inhibitor, HAE hereditary angioedema
aBerinert is approved for intravenous administration to treat acute attacks of HAE in pediatric and adult patients. Subcutaneous administration for on-demand treatment of attacks is unapproved